Additional Relevant Details Lilly announced that it will present data from its multiple phase 3 trials of Ixekizumab for moderate-to-severe plaque psoriasis and active psoriatic arthritis at the annual meeting of the American Academy of Dermatology.  The data will be presented over the course of 5 days.